JCVI advises extending COVID-19 booster programme
All adults aged 40- to 49-years-old to be offered an mRNA vaccine booster dose
Read More
Tag: JCVI
JCVI does not recommend COVID-19 vaccination for all 12 to 15-year-olds
UK’s chief medical officers will now provide ‘further advice’ on COVID-19 vaccination in this age group
Read More
JCVI advises booster COVID-19 jab for severely immunosuppressed
Offer is separate to potential booster programme
Read More
16- and 17-year-olds should receive first COVID-19 vaccine, advises JCVI
Vaccine side effects rare and outweighed by the benefits
Read More
New advice issued on COVID-19 vaccination of children and young people
The UK’s JCVI has advised vulnerable children should be offered Pfizer/BioNTech vaccines
Read More
JCVI recommends booster COVID-19 jabs for most vulnerable groups
Interim advice says boosters could be offered to priority groups from September
Read More
New advice on COVID-19 vaccination for pregnant women in UK
JCVI advises pregnant women in the UK be offered COVID-19 vaccination at the same time as the rest of the population
Read More
HPV jab will be given to boys in England, gov’t confirms
The government has confirmed that boys in England will be vaccinated against the human papilloma virus in line with recent recommendations from the Joint Committee on Vaccination and Immunisation (JCVI).
Read More
JCVI backs HPV jab for boys
Government advisors are recommending that the national HPV immunisation programme in England should include boys as well as girls.
Read More
UK officials reject calls to expand men B vaccination
Campaigners for expanding the scope of routine meningitis B vaccination in the UK say they are disappointed with a decision that a programme in infants aged one to two is not feasible.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
